ILAE British Branch 18th SpR Teaching Weekend

14-15 MAY 2022



Angelini Pharma


Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Industries. The company has several manufacturing sites making pharmaceutical intermediates and medicines.

We are committed to helping patients in the therapeutic areas of Brain Health, Rare Diseases and Consumer Healthcare.

Angelini Pharma operates directly in 25 countries employing more than 3,000 people and commercialises its products in more than 70 countries through strategic alliances with other leading international pharmaceutical groups.

Further information about products available in the UK can be found at

UK11859P | May 2022

Download the brochure
Watch introduction video



UCB is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological and immunological conditions.

Because there is no such thing as an ‘average patient’ we use the tools, channels and scientific advances at our disposal to develop a deep understanding of a disease and the real needs of patients.

Working in collaboration with leading researchers from academia, medical charities and industry we strive to deliver cutting-edge science, innovative drugs and practical solutions patients need to improve their quality of life.

We are inspired by patients. Driven by science.

UCBCaresforNeurology: A promotional site for HCPs that brings together information related to Epilepsy and Parkinson’s Disease:

IE-N-DA-EPI-2100018 DOP Dec 2021

UNEEG medical


UNEEG medical is an entrepreneurial, ambitious company specialising in ultra long-term subcutaneous EEG for remote monitoring of brain activity in a real-life setting. Ultra long-term, objective seizure tracking represents a new way forward for epilepsy care, and complements the tools currently available.

Our CE marked 24/7 EEGTM SubQ solution collects and analyses EEG data day and night for up to 15 months and provides the epilepsy community with more accurate knowledge of seizures to support improvement in epilepsy care.

The company Headquarters are based in Denmark and now has subsidiaries in other countries including the UK, where active study sites have been initiated in both Kings College London, and Beaumont Hospital in Dublin, led by Prof. Mark Richardson and Prof. Norman Delanty respectively.

Download the brochure



Zogenix is a global biopharmaceutical company committed to developing and commercialising therapies with the potential to transform the lives of patients and their families living with rare diseases. We have a special interest in rare epilepsies, including Dravet syndrome.

Fintepla▼(fenfluramine), indicated for adults and children ≥ 2 years,* offers hope of seizure freedom that could open up a whole new world to those living with Dravet syndrome.1

We are delighted that this new standard for seizure control in Dravet syndrome is being launched in the UK in 2022.

For further information, please visit

Prescribing information can be found here

*Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.1

Fintepla is currently under NICE evaluation.

1. Fintepla Summary of Product Characteristics.

UK-FIN1-2200035 March 2022



LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart.

Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide.

For further information, please visit

Desitin Pharma


Desitin is an independent, medium sized, pharmaceutical company specialising in the manufacture and supply of age- and ability-appropriate formulations of anti-epileptic drugs, intended to help support adherence and therefore help patient outcomes. Prescribing Information.